DOCARNO
0816.783.550 · rovalta.com · 22/09/2026
ACTIVE
DOCARNO
Financial year 2024 · closed on 31/12/2024
Net result
34,2 k €
+5.9% YoY
Revenue
199,4 k €
+4.4% YoY
Equity
-2,1 k €
+94.2% YoY
Overview
What does DOCARNO do?
DOCARNO is a Private limited company incorporated in 2009. Its main activity is: Specialist medical practice activities. Its registered office is in Molenbeek-Saint-Jean.
Legal situation
● Normal situation
BCE/KBO no. / VAT
BE 0816.783.550
Incorporation
06/07/2009
Legal form
Private limited company
Registered office
Rue de l'Idylle 31
1080 Molenbeek-Saint-Jean · BruxellesSee on map
1080 Molenbeek-Saint-Jean · BruxellesSee on map
Contributed capital
18 600,00 €
Latest accounts
31/12/2024
Activities (NACE)
Contacts
1 public detail availableLog in to view
Signals
ProfitablePositive cashflowPositive EBITDA
Available with a Rovalta subscriptionTry for 7 days
Financials
Trend over 15 financial years
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||||||||||||||||||||
| Revenue | 199,4 k € | +4.4% | 191,1 k € | -18.8% | 235,3 k € | +38.1% | 170,3 k € | +25.3% | 135,9 k € | +743% | 16,1 k € | – | – | 272 k € | – | – | – | – | – | – | |||||||||
| EBITDA | 44,6 k € | +2.5% | 43,5 k € | -38.7% | 70,9 k € | +14.2% | 62 k € | +38.4% | 44,8 k € | +239% | 13,2 k € | – | – | 64,3 k € | +41975% | -153,6 € | 0 € | +100% | -152,7 € | +90.6% | -1,6 k € | +45.6% | -3 k € | -30.0% | -2,3 k € | ||||
| Operating result | 34,6 k € | +5.2% | 32,9 k € | -45.8% | 60,6 k € | +16.9% | 51,9 k € | +40.8% | 36,9 k € | +181% | 13,1 k € | – | – | 64,3 k € | +347% | -26 k € | +5.5% | -27,5 k € | +5.8% | -29,2 k € | +4.8% | -30,7 k € | +4.2% | -32,1 k € | -2.2% | -31,4 k € | |||
| Net result | 34,2 k € | +5.9% | 32,3 k € | -46.3% | 60,2 k € | +17.5% | 51,2 k € | +43.1% | 35,8 k € | +173% | 13,1 k € | +46506% | -28,2 € | -1.1% | -27,9 € | -100% | 48 k € | +224% | -38,7 k € | +4.3% | -40,5 k € | +12.2% | -46,1 k € | -1.6% | -45,4 k € | +7.4% | -49 k € | +0.0% | -49 k € |
| Balance sheet | |||||||||||||||||||||||||||||
| Equity | -2,1 k € | +94.2% | -36,3 k € | +47.1% | -68,6 k € | +46.7% | -128,8 k € | +28.5% | -180 k € | +16.6% | -215,8 k € | +5.7% | -228,9 k € | -0.0% | -228,9 k € | -0.0% | -228,9 k € | +19.0% | -282,5 k € | -15.9% | -243,8 k € | -19.9% | -203,3 k € | -29.3% | -157,2 k € | -40.6% | -111,9 k € | -77.9% | -62,9 k € |
| Total assets | 30,2 k € | -19.1% | 37,4 k € | -18.7% | 46 k € | +24.8% | 36,8 k € | -16.9% | 44,3 k € | -20.5% | 55,8 k € | +14859% | 372,8 € | -7.0% | 401 € | -6.5% | 428,9 € | -99.8% | 197,1 k € | -11.7% | 223,3 k € | -11.0% | 250,7 k € | -10.4% | 279,8 k € | -9.4% | 308,7 k € | -8.6% | 337,9 k € |
| Cash | 20,8 k € | -1.8% | 21,2 k € | -16.0% | 25,3 k € | +290% | 6,5 k € | -48.4% | 12,5 k € | -21.7% | 16 k € | +4196% | 372,8 € | -7.0% | 401 € | -6.5% | 428,9 € | – | 266,3 € | +43.6% | 185,5 € | +43.6% | 129,2 € | – | 89,7 € | ||||
| Debts | 32,3 k € | -56.1% | 73,7 k € | -35.7% | 114,6 k € | -30.8% | 165,7 k € | -26.2% | 224,4 k € | -17.4% | 271,6 k € | +18.4% | 229,3 k € | 0.0% | 229,3 k € | 0.0% | 229,3 k € | -52.2% | 479,6 k € | +2.7% | 467,1 k € | +2.9% | 454,1 k € | +3.9% | 437 k € | +3.9% | 420,6 k € | +4.9% | 400,8 k € |
Estimate
Indicative valuation
As an indication, this company is worth
between 100 k€ and 250 k€
See the valuationGovernance
Board of directors
Seen on filing of 31/12/2024 · 2 active · 4 ended
Active mandates
ARNAUD VAN OSSELT
Activesophie leemans
ActiveEnded mandates
ARNAUD VAN OSSELT
EndedARNAUD VAN OSSELT
EndedARNAUD VAN OSSELT
EndedPASCAL VANDEN BERGH
EndedAt this address
Other companies at this address
| Company | CBE no. |
|---|---|
Medical Events and Discoveries● Active | 1027.182.389 |
Financials
Annual accounts
Full financial information
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
| Type of account | Micro model | Micro model | Micro model | Micro model | Micro model | Micro model |
| Start of the financial year | 01/01/2024 | 01/01/2023 | 01/01/2022 | 01/01/2021 | 01/01/2020 | 01/01/2019 |
| Closing of the financial year | 31/12/2024 | 31/12/2023 | 31/12/2022 | 31/12/2021 | 31/12/2020 | 31/12/2019 |
| Length of the financial year | 12 months | 12 months | 12 months | 12 months | 12 months | 12 months |
| Filing date | 27/08/2025 | 29/07/2024 | 26/07/2023 | 30/08/2022 | 09/09/2021 | 13/08/2020 |
| General meeting | 14/06/2025 | 08/06/2024 | 10/06/2023 | 11/06/2022 | 05/06/2021 | 06/06/2020 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Ratios
Financial ratios
Looking for more information about this company?
Try for 7 daysFilings
Annual accounts filings
15 filings with the NBB
| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Micro model | 31/12/2024 | 14/06/2025 | 27/08/2025 | French | |
| Micro model | 31/12/2023 | 08/06/2024 | 29/07/2024 | French | |
| Micro model | 31/12/2022 | 10/06/2023 | 26/07/2023 | French | |
| Micro model | 31/12/2021 | 11/06/2022 | 30/08/2022 | French | |
| Micro model | 31/12/2020 | 05/06/2021 | 09/09/2021 | French | |
| Micro model | 31/12/2019 | 06/06/2020 | 13/08/2020 | French | |
| Micro model | 31/12/2018 | 08/06/2019 | 16/08/2019 | French | |
| Micro model | 31/12/2017 | 09/06/2018 | 25/07/2018 | French | |
| Micro model | 31/12/2016 | 10/06/2017 | 30/08/2017 | French | |
| Abridged model | 31/12/2015 | 11/06/2016 | 27/07/2016 | French | |
| Abridged model | 31/12/2014 | 13/06/2015 | 28/07/2015 | French | |
| Abridged model | 31/12/2013 | 14/06/2014 | 28/07/2014 | French | |
| Abridged model | 31/12/2012 | 13/06/2013 | 02/08/2013 | French | |
| Abridged model | 31/12/2011 | 12/06/2012 | 27/07/2012 | French | |
| Abridged model | 31/12/2010 | 11/06/2011 | 30/08/2011 | French |
Valuation
Estimate
Indicative valuation
Order of magnitude
As an indication, this company is worth
between 100 k€ and 250 k€
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Disclaimer
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Governance
Board of directors
Seen on filing of 31/12/2024 · 2 active · 4 ended
Active mandates
ARNAUD VAN OSSELT
Activesophie leemans
ActiveEnded mandates
ARNAUD VAN OSSELT
EndedARNAUD VAN OSSELT
EndedARNAUD VAN OSSELT
EndedPASCAL VANDEN BERGH
EndedShareholders
Ownership and network
Looking for more information about this company?
Try for 7 daysPublications
Belgian Official Gazette
Belgian Official Gazette publications
Source: Belgian Official Gazette
Similar companies
Competition
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2024Annual accounts 202434,2 k €↑
- 2023Annual accounts 202332,3 k €↓
- 2023Name changeDOCARNO
- 2022Annual accounts 202260,2 k €↑
- 2021Annual accounts 202151,2 k €↑
- 2021Name changeDOCTEUR PATRICIA JETTEN ASHER
- 2020Annual accounts 202035,8 k €↑
- 2019Annual accounts 201913,1 k €↑
- 2018Annual accounts 2018-28,2 €↓
- 2017Annual accounts 2017-27,9 €↓
- 2016Annual accounts 201648 k €↑
- 2015Annual accounts 2015-38,7 k €↑
- 2014Annual accounts 2014-40,5 k €↑
- 2013Annual accounts 2013-46,1 k €↓
- 2012Annual accounts 2012-45,4 k €↑
- 2011Annual accounts 2011-49 k €↑
- 2010Annual accounts 2010-49 k €
- 06/07/2009IncorporationPrivate limited company